RIGL Stock Analysis: Rigel Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 716m USD | 12M Return: 125.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.2M
Qual. Beats: 0
Rev. Trend: 94.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Rigel Pharmaceuticals is a U.S.-based biotechnology company that develops and commercializes therapies for hematologic disorders and cancer. The company markets three approved products: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia, and GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer and thyroid cancer. GAVRETO is part of a global collaboration with Roche, reflecting a common biotech business model in which smaller companies partner with larger pharmaceutical firms to co-develop and commercialize targeted oncology therapies.
Beyond its commercial portfolio, Rigel is advancing a clinical pipeline that includes R289, an oral IRAK1/4 inhibitor being studied in hematology-oncology, autoimmune, and inflammatory indications. The company also maintains research collaborations with The University of Texas MD Anderson Cancer Center and the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) to explore olutasidenib in additional IDH1-mutated cancers. Incorporated in 1996 and headquartered in South San Francisco, Rigel operates within the broader biotechnology sector, where companies typically depend on a mix of product revenue, partnerships, and pipeline development to sustain long-term growth.
- REZLIDHIA and TAVALISSE net product sales growth trajectory
- R289 Phase 1b readout in lower-risk MDS approaches
- Cash burn raises potential dilutive capital raise risk
| Net Income: 364.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -4.37 > 1.0 |
| NWC/Revenue: 48.22% < 20% (prev 39.36%; Δ 8.85% < -1%) |
| CFO/TA 0.16 > 3% & CFO 79.3m > Net Income 364.2m |
| Net Debt (-100.1m) to EBITDA (131.3m): -0.76 < 3 |
| Current Ratio: 2.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.7m) vs 12m ago 8.35% < -2% |
| Gross Margin: 93.39% > 18% (prev 89.64%; Δ 3.75% > 0.5%) |
| Asset Turnover: 88.09% > 50% (prev 115.4%; Δ -27.31% > 0%) |
| Interest Coverage Ratio: 18.68 > 6 (EBIT TTM 128.9m / Interest Expense TTM 6.90m) |
| A: 0.29 (Total Current Assets 234.0m - Total Current Liabilities 89.5m) / Total Assets 504.6m |
| B: -2.01 (Retained Earnings -1.01b / Total Assets 504.6m) |
| C: 0.38 (EBIT TTM 128.9m / Avg Total Assets 340.3m) |
| D: 3.82 (Book Value of Equity 399.9m / Total Liabilities 104.7m) |
| Altman-Z'' = 1.88 = BBB |
| DSRI: 0.81 (Receivables 49.9m/41.5m, Revenue 299.8m/203.1m) |
| GMI: 0.96 (GM 89.64% / 93.39%) |
| AQI: 3.36 (AQ_t 0.53 / AQ_t-1 0.16) |
| SGI: 1.48 (Revenue 299.8m / 203.1m) |
| TATA: 0.56 (NI 364.2m - CFO 79.3m) / TA 504.6m) |
| Beneish M = -1.42 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 42.56 with a total of 744,387 shares traded. Over the past week, the price has changed by +9.02%, over one month by +41.49%, over three months by +48.14% and over the past year by +125.90%.
Current recommended Stop Loss: 38.60 (which is 9.3% or 2.5 ATR below the current price).
Rigel Pharmaceuticals has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold RIGL.
- StrongBuy: 1
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.2 | 27.3% |
P/E Trailing = 2.0073
P/E Forward = 8.5106
P/S = 2.3899
P/B = 1.7716
P/EG = -0.1
Revenue TTM = 299.8m USD
EBIT TTM = 128.9m USD
EBITDA TTM = 131.3m USD
Long Term Debt = 15.0m USD (from longTermDebt, last quarter)
Short Term Debt = 30.5m USD (from shortTermDebt, last quarter)
Debt = 46.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 864k
Net Debt = -100.1m USD (calculated: Debt 46.6m - CCE 146.7m)
Enterprise Value = 616.3m USD (716.4m + Debt 46.6m - CCE 146.7m)
Interest Coverage Ratio = 18.68 (Ebit TTM 128.9m / Interest Expense TTM 6.90m)
EV/FCF = 7.77x (Enterprise Value 616.3m / FCF TTM 79.3m)
FCF Yield = 12.86% (FCF TTM 79.3m / Enterprise Value 616.3m)
FCF Margin = 26.44% (FCF TTM 79.3m / Revenue TTM 299.8m)
Net Margin = 121.5% (Net Income TTM 364.2m / Revenue TTM 299.8m)
Gross Margin = 93.39% ((Revenue TTM 299.8m - Cost of Revenue TTM 19.8m) / Revenue TTM)
Gross Margin QoQ = 92.17% (prev 91.47%)
Tobins Q-Ratio = 1.22 (Enterprise Value 616.3m / Total Assets 504.6m)
Interest Expense / Debt = 14.81% (Interest Expense 6.90m / Debt 46.6m)
Taxrate = 25.76% (3.00m / 11.7m)
NOPAT = 95.7m (EBIT 128.9m * (1 - 25.76%))
Current Ratio = 2.62 (Total Current Assets 234.0m / Total Current Liabilities 89.5m)
Debt / Equity = 0.12 (Debt 46.6m / totalStockholderEquity, last quarter 399.9m)
Debt / EBITDA = -0.76 (Net Debt -100.1m / EBITDA 131.3m)
Debt / FCF = -1.26 (Net Debt -100.1m / FCF TTM 79.3m)
Total Stockholder Equity = 247.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 107.0% (Net Income 364.2m / Total Assets 504.6m)
RoE = 147.0% (Net Income TTM 364.2m / Total Stockholder Equity 247.7m)
RoCE = 49.05% (EBIT 128.9m / Capital Employed (Equity 247.7m + L.T.Debt 15.0m))
RoIC = 22.22% (NOPAT 95.7m / Invested Capital 430.6m)
WACC = 10.25% (E(716.4m)/V(763.0m) * Re(10.20%) + D(46.6m)/V(763.0m) * Rd(14.81%) * (1-Tc(0.26)))
Discount Rate = 10.20% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.51%
[DCF] Terminal Value 72.08% ; FCFF base≈61.7m ; Y1≈70.7m ; Y5≈104.1m
[DCF] Fair Price = 68.80 (EV 1.17b - Net Debt -100.1m = Equity 1.27b / Shares 18.5m; r=10.25% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.66 | # QB: 0
Revenue Correlation: 94.57 | Revenue CAGR: 48.55% | SUE: -0.36 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=-119.97% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.22 | Chg30d=-3.92% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=2.92 | Chg30d=-5.59% | Revisions=-50% | GrowthEPS=-54.6% | GrowthRev=-6.0%
EPS next Year (2027-12-31): EPS=4.78 | Chg30d=+4.31% | Revisions=+17% | GrowthEPS=+63.9% | GrowthRev=+19.6%
[Analyst] Revisions Ratio: -36% (up=2, down=6)